Mandelic acid condensation polymer: Novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry

Betsy Herold, I. Scordi-Bello, Natalia V. Cheshenko, D. Marcellino, M. Dzuzelewski, F. Francois, R. Morin, V. Mas Casullo, R. A. Anderson, C. Chany, D. P. Waller, L. J D Zaneveld, M. E. Klotman

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Presently marketed vaginal barrier methods are cytotoxic and damaging to the vaginal epithelium and natural vaginal flora when used frequently. Novel noncytotoxic agents are needed to protect men and women from sexually transmitted diseases. One novel candidate is a mandelic acid condensation polymer, designated SAMMA. The spectrum and mechanism of antiviral activity were explored using clinical isolates and laboratory-adapted strains of human immunodeficiency virus (HIV) and herpes simplex virus (HSV). SAMMA is highly effective against all CCR5 and CXCR4 isolates of HIV in primary human macrophages and peripheral blood mononuclear cells. SAMMA also inhibits infection of cervical epithelial cells by HSV. Moreover, it exhibits little or no cytotoxicity and has an excellent selectivity index. SAMMA, although not a sulfonated or sulfated polymer, blocks the binding of HIV and HSV to cells by targeting the envelope glycoproteins gp120 and gB-2, respectively, and also inhibits HSV entry postattachment. SAMMA is an excellent, structurally novel candidate microbicide that warrants further preclinical evaluation.

Original languageEnglish (US)
Pages (from-to)11236-11244
Number of pages9
JournalJournal of Virology
Volume76
Issue number22
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

mandelic acid
herpes simplex
Virus Internalization
Human immunodeficiency virus
Simplexvirus
Anti-Infective Agents
polymers
Polymers
anti-infective agents
HIV
viruses
sexually transmitted diseases
mononuclear leukocytes
cytotoxicity
glycoproteins
Sexually Transmitted Diseases
macrophages
epithelial cells
epithelium
flora

ASJC Scopus subject areas

  • Immunology

Cite this

Mandelic acid condensation polymer : Novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry. / Herold, Betsy; Scordi-Bello, I.; Cheshenko, Natalia V.; Marcellino, D.; Dzuzelewski, M.; Francois, F.; Morin, R.; Casullo, V. Mas; Anderson, R. A.; Chany, C.; Waller, D. P.; Zaneveld, L. J D; Klotman, M. E.

In: Journal of Virology, Vol. 76, No. 22, 2002, p. 11236-11244.

Research output: Contribution to journalArticle

Herold, B, Scordi-Bello, I, Cheshenko, NV, Marcellino, D, Dzuzelewski, M, Francois, F, Morin, R, Casullo, VM, Anderson, RA, Chany, C, Waller, DP, Zaneveld, LJD & Klotman, ME 2002, 'Mandelic acid condensation polymer: Novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry', Journal of Virology, vol. 76, no. 22, pp. 11236-11244. https://doi.org/10.1128/JVI.76.22.11236-11244.2002
Herold, Betsy ; Scordi-Bello, I. ; Cheshenko, Natalia V. ; Marcellino, D. ; Dzuzelewski, M. ; Francois, F. ; Morin, R. ; Casullo, V. Mas ; Anderson, R. A. ; Chany, C. ; Waller, D. P. ; Zaneveld, L. J D ; Klotman, M. E. / Mandelic acid condensation polymer : Novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry. In: Journal of Virology. 2002 ; Vol. 76, No. 22. pp. 11236-11244.
@article{ec0571d72d984e08871f76a144512b81,
title = "Mandelic acid condensation polymer: Novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry",
abstract = "Presently marketed vaginal barrier methods are cytotoxic and damaging to the vaginal epithelium and natural vaginal flora when used frequently. Novel noncytotoxic agents are needed to protect men and women from sexually transmitted diseases. One novel candidate is a mandelic acid condensation polymer, designated SAMMA. The spectrum and mechanism of antiviral activity were explored using clinical isolates and laboratory-adapted strains of human immunodeficiency virus (HIV) and herpes simplex virus (HSV). SAMMA is highly effective against all CCR5 and CXCR4 isolates of HIV in primary human macrophages and peripheral blood mononuclear cells. SAMMA also inhibits infection of cervical epithelial cells by HSV. Moreover, it exhibits little or no cytotoxicity and has an excellent selectivity index. SAMMA, although not a sulfonated or sulfated polymer, blocks the binding of HIV and HSV to cells by targeting the envelope glycoproteins gp120 and gB-2, respectively, and also inhibits HSV entry postattachment. SAMMA is an excellent, structurally novel candidate microbicide that warrants further preclinical evaluation.",
author = "Betsy Herold and I. Scordi-Bello and Cheshenko, {Natalia V.} and D. Marcellino and M. Dzuzelewski and F. Francois and R. Morin and Casullo, {V. Mas} and Anderson, {R. A.} and C. Chany and Waller, {D. P.} and Zaneveld, {L. J D} and Klotman, {M. E.}",
year = "2002",
doi = "10.1128/JVI.76.22.11236-11244.2002",
language = "English (US)",
volume = "76",
pages = "11236--11244",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "22",

}

TY - JOUR

T1 - Mandelic acid condensation polymer

T2 - Novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry

AU - Herold, Betsy

AU - Scordi-Bello, I.

AU - Cheshenko, Natalia V.

AU - Marcellino, D.

AU - Dzuzelewski, M.

AU - Francois, F.

AU - Morin, R.

AU - Casullo, V. Mas

AU - Anderson, R. A.

AU - Chany, C.

AU - Waller, D. P.

AU - Zaneveld, L. J D

AU - Klotman, M. E.

PY - 2002

Y1 - 2002

N2 - Presently marketed vaginal barrier methods are cytotoxic and damaging to the vaginal epithelium and natural vaginal flora when used frequently. Novel noncytotoxic agents are needed to protect men and women from sexually transmitted diseases. One novel candidate is a mandelic acid condensation polymer, designated SAMMA. The spectrum and mechanism of antiviral activity were explored using clinical isolates and laboratory-adapted strains of human immunodeficiency virus (HIV) and herpes simplex virus (HSV). SAMMA is highly effective against all CCR5 and CXCR4 isolates of HIV in primary human macrophages and peripheral blood mononuclear cells. SAMMA also inhibits infection of cervical epithelial cells by HSV. Moreover, it exhibits little or no cytotoxicity and has an excellent selectivity index. SAMMA, although not a sulfonated or sulfated polymer, blocks the binding of HIV and HSV to cells by targeting the envelope glycoproteins gp120 and gB-2, respectively, and also inhibits HSV entry postattachment. SAMMA is an excellent, structurally novel candidate microbicide that warrants further preclinical evaluation.

AB - Presently marketed vaginal barrier methods are cytotoxic and damaging to the vaginal epithelium and natural vaginal flora when used frequently. Novel noncytotoxic agents are needed to protect men and women from sexually transmitted diseases. One novel candidate is a mandelic acid condensation polymer, designated SAMMA. The spectrum and mechanism of antiviral activity were explored using clinical isolates and laboratory-adapted strains of human immunodeficiency virus (HIV) and herpes simplex virus (HSV). SAMMA is highly effective against all CCR5 and CXCR4 isolates of HIV in primary human macrophages and peripheral blood mononuclear cells. SAMMA also inhibits infection of cervical epithelial cells by HSV. Moreover, it exhibits little or no cytotoxicity and has an excellent selectivity index. SAMMA, although not a sulfonated or sulfated polymer, blocks the binding of HIV and HSV to cells by targeting the envelope glycoproteins gp120 and gB-2, respectively, and also inhibits HSV entry postattachment. SAMMA is an excellent, structurally novel candidate microbicide that warrants further preclinical evaluation.

UR - http://www.scopus.com/inward/record.url?scp=0036827915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036827915&partnerID=8YFLogxK

U2 - 10.1128/JVI.76.22.11236-11244.2002

DO - 10.1128/JVI.76.22.11236-11244.2002

M3 - Article

C2 - 12388683

AN - SCOPUS:0036827915

VL - 76

SP - 11236

EP - 11244

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 22

ER -